## Edgar Filing: Clovis Oncology, Inc. - Form 4

Clovis Onc Form 4	ology, Inc.										
June 08, 20	)17										
FORM	ЛЛ								OMB APPROVAL		
	UNITED	STATES		RITIES A shington			COMMISSION	N OMB Number:	3235-0287		
Check t if no lo subject Section	to SIAIEN	/IENT OI	Expires:	0							
Form 4 Form 5 obligati may co <i>See</i> Inst 1(b).	Filed put	a) of the l	Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					response			
(Print or Type	e Responses)										
1. Name and Address of Reporting Person <u>*</u> GRAHAM GINGER L			2. Issuer Name <b>and</b> Ticker or Trading Symbol Clovis Oncology, Inc. [CLVS]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First)	Middle)		of Earliest T	_	_	(Check all applicable)				
INC., 5500	(First) (1 VIS ONCOLOGY, ) FLATIRON .Y, SUITE 100			Day/Year)	ransaction		X Director Officer (giv below)		% Owner her (specify		
(Street) 4. If Amendmen Filed(Month/Day/					Day/Year) Applicable Line) _X_ Form filed by G			One Reporting P	int/Group Filing(Check One Reporting Person Iore than One Reporting		
BOULDE	R, CO 80301						Person	More than One R	ceporting		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	e Securities A	cquired, Disposed	of, or Beneficia	ally Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	l (A) or l of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly o	or indirectly.				
					inforı requi	nation cont red to respe ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					sposed of, or convertible	Beneficially Owned securities)	1			
		action Date /Day/Year)			4. Transact	5. Number iorDerivative			7. Title and Amount of 8 Underlying Securities I		

### Edgar Filing: Clovis Oncology, Inc. - Form 4

Security (Instr. 3)			any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)			
				Code V	(A) (D	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	\$ 59.56	06/08/2017		А	10,000	<u>(1)</u>	06/08/2027	Common Stock	10,000			
Reporting Owners												
Re	<b>Reporting Owner Name / Address</b>			<b>Relation</b> 10% Owne	-	Other						
GRAHAM GINGER L C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301			100 X									
Signa	tures											
/s/ Ginge Graham	r	06/08/2017										
<u>**</u> Signat	ure of	Date										

#### \*\*Signature of Reporting Person

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (